Install
조선비즈는 국내 최고의 온라인 경제 전문 미디어로, 정책, 금융, 부동산, 기업, 글로벌 경제 등 정보를 제공합니다.
- 9,798articles · 30d
- 23+ min agolatest article
- Aug 15, 2026earliest in window
- 89%with images
- 100avg words
- south korea 3,437
- business information 3,328
- politics 3,075
- society 2,859
- entertainment 2,722
- hallyu 2,699
- korea news 2,668
- korean entertainment 2,646
- celebrity 2,632
- sports 2,589
- the asia business daily 2,549
- newspaper 2,496
- korea 2,451
- economic 2,403
- issue 2,309
- k-drama 2,275
- k-variety 2,252
- kst 2,075
- business 1,760
- k-pop 1,543
- Entertainment 3,279
- Arts & Entertainment 2,863
- Sports & Fitness 2,424
- Economy, Business & Finance 2,340
- Sports 2,286
- Sport 2,131
- Human Interest 1,987
- Arts, Culture, Entertainment & Media 1,841
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Aribio and AriBio LAB launch Alzheimer vaccine drive targeting neuroinflammation
3+ week, 2+ day ago (14+ words) Aribio Lab and Aribio launch Alzheimer vaccine program targeting amyloid, tau, inflammation - CHOSUNBIZ Chosunbiz...
Moderna spurs RNA cancer vaccine race as South Korea firms chase delivery edge
3+ week, 4+ day ago (15+ words) CHOSUNBIZ Chosunbiz...
Keytruda plus personalized mRNA vaccine tops melanoma trial, lifts Moderna
3+ week, 4+ day ago (515+ words) Personalized mRNA shot with Keytruda delays melanoma's return, sparking a premarket surge for Moderna A personalized mRNA Vaccine cancer vaccine co-developed by Moderna and Merck (MSD) met its primary endpoint in a phase 3 melanoma trial. Compared with giving the immunotherapy…...
Neoimmunetech licenses NT-I7 rights to U.S. biotech in $260 million deal
3+ week, 4+ day ago (290+ words) Neoimmunetech(950220) signed its first technology transfer deal since listing on KOSDAQ. It will hand over rights to develop and commercialize the immuno-oncology candidate "NT-I7" related to thymic dysfunction to a U.S. biotech and receive up to $260 million (about 366.9 billion won) in…...